{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["De Michieli L"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS","Mayo Clinic CTSA","National Institutes of Health","NIH HHS"],"pagination":["1080-1089"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8083261"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["67(8)"],"pubmed_abstract":["<h4>Background</h4>Limited data exist on high-sensitivity cardiac troponin (hs-cTn) for risk-stratification in COVID-19.<h4>Methods</h4>We conducted a multicenter, retrospective, observational, US-based study of COVID-19 patients undergoing hs-cTnT. Outcomes included short-term mortality (in-hospital and 30-days post-discharge) and a composite of major adverse events, including respiratory failure requiring mechanical ventilation, cardiac arrest, and shock within the index presentation and/or mortality during the index hospitalization or within 30-days post-discharge.<h4>Results</h4>Among 367 COVID-19 patients undergoing hs-cTnT, myocardial injury was identified in 46%. They had a higher risk for mortality (20% vs 12%, P < 0.0001; unadjusted HR 4.44, 95% CI 2.13-9.25, P < 0.001) and major adverse events (35% vs. 11%, P < 0.0001; unadjusted OR 4.29, 95% CI 2.50-7.40, P < 0.0001). Myocardial injury was associated with major adverse events (adjusted OR 3.84, 95% CI 2.00-7.36, P < 0.0001) but not mortality. Baseline (adjusted OR 1.003, 95% CI 1.00-1.007, P = 0.047) and maximum (adjusted OR 1.005, 95% CI 1.001-1.009, P = 0.0012) hs-cTnT were independent predictors of major adverse events. Most (95%) increases were due to myocardial injury, with 5% (n = 8) classified as type 1 or 2 myocardial infarction. A single hs-cTnT <6 ng/L identified 26% of patients without mortality, with a 94.9% (95% CI 87.5-98.6) negative predictive value and 93.1% sensitivity (95% CI 83.3-98.1) for major adverse events in those presenting to the ED.<h4>Conclusions</h4>Myocardial injury is frequent and prognostic in COVID-19. While most hs-cTnT increases are modest and due to myocardial injury, they have important prognostic implications. A single hs-cTnT <6 ng/L at presentation may facilitate the identification of patients with a favorable prognosis."],"journal":["Clinical chemistry"],"pubmed_title":["High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19."],"pmcid":["PMC8083261"],"funding_grant_id":["UL1TR002377","UL1 TR002377"],"pubmed_authors":["Mehta RA","Knott JD","Jaffe AS","De Michieli L","Sandoval Y","Yang EH","Akula A","Gulati R","Singh G","Hodge DO","Ola O","Singh R","Gharacholou M","Dworak M"],"additional_accession":[]},"is_claimable":false,"name":"High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19.","description":"<h4>Background</h4>Limited data exist on high-sensitivity cardiac troponin (hs-cTn) for risk-stratification in COVID-19.<h4>Methods</h4>We conducted a multicenter, retrospective, observational, US-based study of COVID-19 patients undergoing hs-cTnT. Outcomes included short-term mortality (in-hospital and 30-days post-discharge) and a composite of major adverse events, including respiratory failure requiring mechanical ventilation, cardiac arrest, and shock within the index presentation and/or mortality during the index hospitalization or within 30-days post-discharge.<h4>Results</h4>Among 367 COVID-19 patients undergoing hs-cTnT, myocardial injury was identified in 46%. They had a higher risk for mortality (20% vs 12%, P < 0.0001; unadjusted HR 4.44, 95% CI 2.13-9.25, P < 0.001) and major adverse events (35% vs. 11%, P < 0.0001; unadjusted OR 4.29, 95% CI 2.50-7.40, P < 0.0001). Myocardial injury was associated with major adverse events (adjusted OR 3.84, 95% CI 2.00-7.36, P < 0.0001) but not mortality. Baseline (adjusted OR 1.003, 95% CI 1.00-1.007, P = 0.047) and maximum (adjusted OR 1.005, 95% CI 1.001-1.009, P = 0.0012) hs-cTnT were independent predictors of major adverse events. Most (95%) increases were due to myocardial injury, with 5% (n = 8) classified as type 1 or 2 myocardial infarction. A single hs-cTnT <6 ng/L identified 26% of patients without mortality, with a 94.9% (95% CI 87.5-98.6) negative predictive value and 93.1% sensitivity (95% CI 83.3-98.1) for major adverse events in those presenting to the ED.<h4>Conclusions</h4>Myocardial injury is frequent and prognostic in COVID-19. While most hs-cTnT increases are modest and due to myocardial injury, they have important prognostic implications. A single hs-cTnT <6 ng/L at presentation may facilitate the identification of patients with a favorable prognosis.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-29T11:30:23.415Z","creation":"2025-04-06T19:53:55.162Z"},"accession":"S-EPMC8083261","cross_references":{"pubmed":["33860295"],"doi":["10.1093/clinchem/hvab062"]}}